Glibclay 4 Tablet contains Glimepiride 4mg, a potent sulfonylurea that helps improve glycemic control in patients with type-2 diabetes mellitus. It effectively stimulates pancreatic insulin secretion and assists in maintaining blood glucose levels within the desired range.
Glimepiride enhances the body's insulin response to elevated blood sugar, providing regulation of both fasting and postprandial glucose levels. Its once-daily oral administration ensures convenience and promotes patient compliance in long-term diabetes management.
This tablet is suitable for patients inadequately controlled by diet, exercise, or monotherapy, offering proven efficacy with a safe and tolerable profile. It is widely used in both outpatient and hospital-based diabetes care.
Adding Glibclay 4 Tablet to your diabetes and metabolic-care portfolio expands your product range, providing opportunities in retail pharmacy distribution, hospital procurement, institutional orders, export channels, and third-party manufacturing. Its high prescription demand guarantees steady commercial performance.